CDSCO empowers regulators & boosts exports through comprehensive training programmes

Posted on Updated on


In a concerted effort to fortify regulatory capabilities and enhance pharmaceutical exports, the Central Drugs Standard Control Organisation (CDSCO) has orchestrated a series of impactful training initiatives in the fiscal year 2023-24. With a focus on equipping regulators with advanced skills, the CDSCO conducted 23 residential training programmes tailored to address critical aspects such as risk-based inspections, prosecution launches, adoption of new therapies, and harnessing technology in Industry 4.0.

These training sessions, meticulously designed to ensure regulatory efficacy and adherence to revised Schedule M regulations, saw the successful participation of 1,100 regulators. Among them were 700 officials from CDSCO and 400 state drug regulators, all of whom underwent rigorous pre-assessment and post-assessment tests, with a stringent pass mark set at 70 per cent, to earn the coveted Successful Training Completion Certificate.

The training curriculum extended beyond conventional classroom learning, incorporating dynamic syndicate activities that fostered collaborative problem-solving and knowledge exchange among participants. Notably, the interactive format culminated in insightful presentations by groups of 10 participants, adding depth and diversity to the learning experience.

In parallel, CDSCO’s strategic vision encompassed a broader agenda of promoting pharmaceutical exports, a mission echoed in recent industry gatherings. In a significant development, industry leaders convened in Panjim, Goa, for a comprehensive capacity-building workshop organized by the Pharmaceuticals Export Promotion Council of India (Pharmexcil), in collaboration with the Goa Food and Drug Administration (FDA) and CDSCO.

The workshop, focused on reinforcing quality compliance and ensuring patient safety within the pharmaceutical sector, served as a testament to India’s growing stature as a global pharmacy hub.

Highlighting India’s resilience in the face of global challenges, Uday Bhakar, director general of Pharmexcil, underscored the nation’s robust pharmaceutical supply chain. Bhakar’s remarks were accompanied by encouraging statistics, revealing a noteworthy 9 per cent growth in pharmaceutical exports from April to February 2024. This performance underscored India’s pivotal role in supplying pharmaceutical products to markets across Latin America, Europe, and Africa, further cementing its reputation as a reliable pharmacy to the world.

Source : 1

Let us know what you think!